Skip to content

Aurinia Pharmaceuticals

US · AUPH #2749 by market cap Listed 1970
16.01 +0.32 +2.04%
Live - 5344 symbols - heartbeat 279s ago · 2026-10-08 08:17
Pre-market 16.05 +0.25%
After-hours 16.01 0.00%
Market cap
2.13B
P/B
3.46
EPS
2.07
Reader sentiment Are you bullish or bearish on AUPH?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    RBC Capital Maintains Aurinia Pharmaceuticals(AUPH.US) With Hold Rating, Maintains Target Price $15
    Market Newswire · 2026/2/27
  • TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $17
    Market Newswire · 2026/8/20
  • Rating change
    Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Neumora Therapeutics, Inc. (NMRA) and Aurinia Pharmaceuticals (AUPH)
    TipRanks · 2026/3/31
  • Rating change
    Leerink Partners Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $10
    Market Newswire · 2025/7/2
  • Rating change
    TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $11
    Market Newswire · 2025/8/1
  • Bloom Burton Upgrades Aurinia Pharmaceuticals(AUPH.US) to Buy Rating, Raises Target Price to $21
    Market Newswire · 2026/8/20
  • Rating change
    RBC Capital Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Cuts Target Price to $8
    Market Newswire · 2025/2/28
  • Rating change
    Jefferies Upgrades Aurinia Pharmaceuticals(AUPH.US) to Buy Rating, Raises Target Price to $21
    Market Newswire · 2025/11/7
  • Rating change
    TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Raises Target Price to $17
    Market Newswire · 2025/11/5
  • Earnings Flash (AUPH) Aurinia Pharmaceuticals Posts Q1 EPS $0.25, Vs. FactSet Est of $0.20
    MT Newswires · 2026/5/7
  • Rating change
    Leerink Partners Downgrades Aurinia Pharmaceuticals(AUPH.US) to Hold Rating, Raises Target Price to $16
    Market Newswire · 2025/12/3
  • Earnings Flash (AUPH) Aurinia Pharmaceuticals Inc. Reports Q2 Revenue $83.2M, Vs. FactSet Est of $80.4M
    MT Newswires · 2026/8/6
  • Rating change
    H.C. Wainwright Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $17
    Market Newswire · 2026/2/27
  • Rating change
    TR | OpenAI - 4o Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Raises Target Price to $13
    Market Newswire · 2025/8/6
  • Rating change
    RBC Capital Downgrades Aurinia Pharmaceuticals(AUPH.US) to Hold Rating, Raises Target Price to $15
    Market Newswire · 2025/11/5
  • Rating change
    Bloom Burton Maintains Aurinia Pharmaceuticals(AUPH.US) With Hold Rating, Maintains Target Price $15
    Market Newswire · 2026/3/31
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Aurinia Pharmaceuticals (AUPH) and RegenXBio (RGNX)
    TipRanks · 2025/5/13
  • Aurinia Pharmaceuticals(AUPH.US) 10% Shareholder Buys US$12.46 Million in Common Stock
    Market Newswire · 2026/6/3
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH), MAIA Biotechnology, Inc. (MAIA) and CG Oncology, Inc. (CGON)
    TipRanks · 2026/3/2
  • Rating change
    H.C. Wainwright Initiates Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Announces Target Price $17
    Market Newswire · 2025/7/30

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 08:17:43 · For reference only, not investment advice and not tailored to your situation.